

## BIOGRAPHICAL SKETCH

NAME: Günter U. Höglinger

POSITION TITLE: Professor, Dept. of Neurology, Ludwig-Maximilians University, Munich, Germany

### EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE (if applicable)	Completion Date	FIELD OF STUDY
Regensburg University, Regensburg, Germany	Vordiplom (BSc)	09/1993	Physics
Julius-Maximilians-University, Würzburg, Germany	Approbation (medical license)	01/2000	Clinical Medicine
Philipps-University, Marburg, Germany	MD (summa cum laude)	06/2000	Neuroscience
INSERM U679, Hôpital de la Salpêtrière, Paris, France	Postdoctoral fellow	06/2000- 12/2003	Neuroscience
Dept. of Neurology, Philipps-University, Marburg, Germany	Board-certified Neurologist	09/2007	Neurology
Dept. of Neurology, Philipps-University, Marburg, Germany	Habilitation	04/2007	Neurology

### A. Positions and Honors

#### Positions

Since 01.01.2023 **Director**, Dept. of Neurology, [Ludwig-Maximilians University](#) (LMU) Munich, Germany and **Affiliated Scientist**, [German Center for Neurodegenerative Disorders](#) (DZNE)  
06.2019-12.2022 **Director**, Dept. of Neurology, [Hannover Medical School](#) (MHH), Germany  
2017-2019 **Coordinator of Clinical Research**, [DZNE Munich](#)  
2011-2019 **Full tenured Professor for Translational Neurodegeneration**, DZNE & Technical University Munich,  
2011 **Deputy Director**, Dept. of Neurology, Philipps-University Marburg, Germany  
2007 - 2011 **Consultant in Neurology**, Dept. of Neurology, Philipps-University Marburg  
2004 - 2011 **Head of the Experimental Neurology Unit**, Dept. of Neurology, Philipps-University Marburg  
2001 - 2004 **Postdoc**, Institute of Health and Medical Research, U679, Hôpital Salpêtrière, Paris, France  
1999 - 2001 **Resident physician**, Dept. of Neurology, Philipps University Marburg, Germany  
1999 **Medical trainee**, National Hospital for Neurology, UCL, Queenssquare, London, UK

#### Honours

Since 2020 Co-Founder, Chair of the Scientific Advisory Board, [German Parkinson's Foundation](#)  
2020 **Standout Achievement Award** [CurePSP](#), New York, NY, USA  
2019-2023 President, [German Parkinson's Society](#)  
2017 **Dingebauer Award for Parkinson's research**, [German Society for Neurology](#)  
Since 2015 Member Advisory Board, [Prof. Klaus Thiemann Foundation](#) for Parkinson's research  
Since 2012 Chair, [Intl. Movement Disorders Society-endorsed PSP Study Group](#),  
2011 - 2016 Translational Neurodegeneration, **Heisenberg Excellence Program**, [German Research Council](#)  
Since 2010 Member, Advisory Board, [CurePSP](#), New York, NY, USA

### B. Publications [PubMed](#)-listed publications; [ORCID iD](#) 0000-0001-7587-6187; selection:

1. Franzmeier N, Brendel M, ... Höglinger G#, Ewers M# (# equal contribution) Tau spreading is driven by neuronal connectivity in primary tauopathies - evidence from tau-PET and histopathology. **Nature Communications**, 2022;13:1362
2. Dam T, ..., **Höglinger GU**, ..., Budd Haeberlein S; on behalf of the PASSPORT Study Group. Safety and efficacy of the monoclonal anti-tau antibody gosuranemab in progressive supranuclear palsy: the PASSPORT trial. **Nature Medicine**, 2021 Aug;27(8):1451-1457.
3. Stamelou M, ..., **Höglinger GU**. Evolving concepts for Progressive Supranuclear Palsy and other 4R-tauopathies. **Nature Reviews Neurology**, 2021;17(10):601-620.
4. **Höglinger G**, ..., Florian H, on behalf of the ARISE Investigators\* Evaluation of tilavonemab (ABBV-8E12) in progressive supranuclear palsy: results from a phase 2, randomised, placebo-controlled, multicentre study. **Lancet Neurology**, 2021;20(3):182-192.
5. Levin J, ..., **Höglinger GU**. Efficacy and safety of epigallocatechin gallate for multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled phase III trial. **Lancet Neurology**, 2019;18:724-735.